Overview

Phase III Study to Evaluate the Efficacy and Safety of AD-209

Status:
RECRUITING
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of AD-209
Phase:
PHASE3
Details
Lead Sponsor:
Addpharma Inc.